
EU Approves Eylea™ 8 mg for 6-Month Dosing
EU Approves Eylea™ 8 mg for Extended 6-Month Dosing in nAMD and DME The European Commission (EC) has approved a label extension for Eylea™ 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection), allowing extended treatment intervals of up…